| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00637780 | Arthritis, Juvenile Rheumatoid | Drug: Sulfasalazine | Pfizer | Phase 4 | 2010-06-01 | 2017-01-03 |
| NCT01577966 | Brain Tumor | Drug: Sulfasalazine | University of Alabama at Birmingham | | 2012-01-01 | 2016-10-16 |
| NCT01312129 | Alcohol Dependence | Drug: Sulfasalazine|Drug: Placebo | The Mind Research Network | | 2010-03-01 | 2014-09-18 |
| NCT00554203 | Coronary Artery Disease | Drug: Sulfasalazine | Boston University | | 2003-07-01 | 2008-05-13 |
| NCT01659242 | Rheumatoid Arthritis | Drug: Methotrexate plus sulfasalazine|Drug: Leflunomide | Singapore General Hospital | Phase 4 | 2012-07-01 | 2014-11-26 |
| NCT01667029 | Painful Neuropathy | Drug: Sulfasalazine|Drug: placebo | Massachusetts General Hospital | Phase 2 | 2013-05-01 | 2016-07-12 |
| NCT01198145 | Diarrhea|Gastrointestinal Complications|Unspecified Adult Solid Tumor, Protocol Specific | Drug: sulfasalazine|Other: placebo | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Phase 3 | 2011-04-01 | 2016-07-01 |
| NCT00247962 | Ankylosing Spondylitis | Drug: etanercept|Drug: sulphasalazine (SSZ) | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2005-12-01 | 2012-10-09 |
| NCT00844142 | Moderate to Severe Active Axial Spondyloarthritis | Drug: Etanercept 25mg|Drug: Sulfasalazine | Charite University, Berlin, Germany|Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 | 2005-11-01 | 2009-02-12 |
| NCT00908089 | Rheumatoid Arthritis | Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo | Helsinki University|Seinajoki Central Hospital|Oulu University Hospital|Jyvskyl Central Hospital|Kuopio University Hospital|Satakunta Central Hospital|University of Turku|Rheumatism Foundation Hospital|Orton Invalid Foundation|South Karelia central hospital|Lappi Central Hospital|Central Hospital of Kanta-Hame | Phase 4 | 2003-03-01 | 2015-03-31 |
| NCT03012763 | Pharmacokinetics|Magnetic Resonance Imaging|Administration, Oral | Drug: Paracetamol|Drug: Sulfasalazine|Drug: Fexofenadine|Drug: Valsartan|Device: non-caloric water|Device: caloric drink|Device: grapefruit juice | University Medicine Greifswald | Phase 1 | 2016-04-01 | 2017-01-05 |
| NCT01040195 | Seronegative Spondyloarthropathies | Drug: Methotrexate, Hydroxychloroquine|Drug: Placebo | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Phase 3 | 2009-06-01 | 2013-03-21 |
| NCT00579878 | Rheumatoid Arthritis | Drug: Leflunomide|Drug: Methotrexate-Sulfasalazine-Hydroxychloroquine|Drug: Leflunomide-Sulfasalazine-Hydroxychloroquine|Drug: Leflunomide | University of Nebraska | Phase 3 | 1999-12-01 | 2014-01-02 |
| NCT02434861 | Chemotherapy-induced Nausea and Vomiting | Drug: Rolapitant|Drug: Digoxin|Drug: Sulfasalazine|Drug: Cooperstown Cocktail | Tesaro, Inc. | Phase 1 | 2015-05-01 | 2015-08-21 |
| NCT01689532 | Arthritis, Rheumatoid | Drug: Sirukumab 100 mg|Drug: Sirukumab 50 mg|Drug: Placebo | Janssen Pharmaceutical K.K.|GlaxoSmithKline | Phase 3 | 2012-11-01 | 2016-09-06 |
| NCT00062465 | Rheumatoid Arthritis | Drug: TwHF | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2003-06-01 | 2008-03-03 |
| NCT02930343 | Rheumatoid Arthritis | Drug: Methotrexate|Drug: Leflunomide|Drug: Hydroxychloroquine|Drug: Prednisolone|Drug: Folic Acid|Drug: Sulfasalazine | Jawaharlal Institute of Postgraduate Medical Education & Research | Phase 4 | 2016-09-01 | 2016-10-09 |
| NCT02456363 | Ankylosing Spondylitis | Biological: TNF alpha|Drug: NSAIDs and sulfasalazine | Chung Shan Medical University | Phase 2 | 2009-11-01 | 2015-05-26 |
| NCT02638896 | Ankylosing Spondylitis | Drug: etanercept (Half-Dose)|Drug: etanercept (Full-Dose)|Drug: Sulfasalazine|Drug: Celecoxib | Zhixiang Huang|Health and Family Planning Commission of Guangdong | Phase 4 | 2016-01-01 | 2015-12-24 |
| NCT02634541 | Ankylosing Spondyloarthritis | Drug: Adalimumab|Other: PET/CT imaging | Helsinki University|AbbVie | Phase 4 | 2016-01-01 | 2017-02-22 |
| NCT00953979 | Ankylosing Spondylitis|Treatment | Drug: kunxian capsule | Gu Jieruo|China-Japan Friendship Hospital|Dongguan People's Hospital|Zhujiang Hospital|Huashan Hospital|Sun Yat-sen University | Phase 4 | 2008-01-01 | 2012-01-18 |
| NCT00405275 | Rheumatoid Arthritis | Drug: Etanercept|Drug: methotrexate|Drug: Sulfasalazine|Drug: Hydroxychloroquine|Drug: Placebo, triple|Drug: Placebo, etanercept | VA Office of Research and Development|Canadian Institutes of Health Research (CIHR)|Rheumatoid Arthritis Investigational Network (RAIN)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | | 2007-07-01 | 2013-11-07 |
| NCT02374021 | Arthritis, Rheumatoid | Drug: Methotrexate|Drug: Sulfasalazine|Drug: Hydroxychloroquine|Drug: Etanercept|Drug: Adalimumab | Brigham and Women's Hospital|Columbia University | Phase 4 | 2016-07-01 | 2017-03-21 |
| NCT00520572 | Rheumatoid Arthritis | Drug: AZD9056|Drug: Etanercept|Drug: Placebo | AstraZeneca | Phase 2 | 2007-08-01 | 2013-01-31 |
| NCT01870128 | Rheumatoid Arthritis | Drug: Combination Steroid|Drug: Methotrexate|Drug: Combination | All India Institute of Medical Sciences, New Delhi | Phase 3 | 2009-08-01 | 2013-06-03 |
